Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,598.09 81.82 0.56%
TOPIX 1,179.13 5.76 0.49%
HANG SENG 22,760.24 64.23 0.28%

Presentations, Executive Appointments, and Quarterly Financial Reports - Research Report on Jazz Pharmaceuticals, Insulet, The



   Presentations, Executive Appointments, and Quarterly Financial Reports -
Research Report on Jazz Pharmaceuticals, Insulet, The Cooper Companies, Anika
                    Therapeutics, and Sangamo Biosciences

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 6, 2013

NEW YORK, November 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Jazz
Pharmaceuticals Public Limited Company (NASDAQ: JAZZ), Insulet Corporation
(NASDAQ: PODD), The Cooper Companies Inc. (NYSE: COO), Anika Therapeutics Inc.
(NASDAQ: ANIK), and Sangamo Biosciences Inc. (NASDAQ: SGMO). Today's readers
may access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.

Jazz Pharmaceuticals Public Limited Company Research Report

On November 1, 2013, Jazz Pharmaceuticals Public Limited Company (Jazz
Pharmaceuticals) announced that it will webcast its corporate presentation at
the 2013 Credit Suisse Healthcare Conference on Tuesday, November 12, at 11:30
a.m. MST / 6:30 p.m. GMT in Phoenix, AZ. Jazz Pharmaceuticals reported that
the live webcast and its replay (available for at least one week following the
presentation) may be accessed through the Company's Investor Relations
website. The Full Research Report on Jazz Pharmaceuticals Public Limited
Company - including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/5fe3_JAZZ]

--

Insulet Corporation Research Report

On October 25, 2013, Insulet Corporation (Insulet) announced its participation
in three upcoming investor conferences. Insulet will present at the Stephens
Fall Investor Conference on Wednesday, November 13, 2013 at 1:00 p.m. ET; The
Goldman Sachs Emerging Growth Conference on Thursday, November 14, 2013 at
8:00 a.m. ET; and the 2013 Canaccord Genuity Medical Technology & Diagnostics
Forum on Thursday, November 14, 2013 at 1:00 p.m. ET. The Company reported
that the live audio webcast and its replay may be accessed through its
Investor Relations for 10 days after the presentation. The Full Research
Report on Insulet Corporation - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/75e4_PODD]

--

The Cooper Companies Inc. Research Report

On October 30, 2013, The Cooper Companies Inc. (The Cooper Companies)
announced the appointment of Daniel G. McBride as the Company's Executive Vice
President, Chief Operating Officer, and General Counsel, effective November 1,
2013. Commenting on his appointment, Robert S. Weiss, President and CEO of The
Cooper Companies said, "I am very pleased to announce Dan's appointment to
this new role. He has been instrumental in supporting our growth and
development as a member of my executive team, and this new role will
strengthen our focus on achieving our long-term operational goals." The Full
Research Report on The Cooper Companies Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/9cde_COO]

--

Anika Therapeutics Inc. Research Report

On October 30, 2013, Anika Therapeutics Inc. (Anika Therapeutics) released its
Q3 2013 results. Anika Therapeutics registered total revenues of $17.8 million
in Q3 2013, up 20.2% YoY. The Company posted net income of $5.0 million in Q3
2013, up 201.3% YoY and diluted EPS of $0.33 in Q3 2013, up 200.0% YoY.
Reflecting on the quarter's performance, Charles H. Sherwood, Ph.D., President
and CEO of Anika Therapeutics said, "This was another strong quarter for
Anika, driven by continued product revenue growth in our Orthobiologics
franchise. Net income and earnings per share rose to third-quarter record high
levels, reflecting strong demand for our viscosupplementation products as well
as our ongoing initiatives to improve performance across the business. These
results measure against a weak set of financial comparatives in the third
quarter of 2012, which reflected the temporary decline in product shipments
that we experienced in that year-earlier period. Given the positive demand
outlook for our Orthobiologics products and the improved efficiencies in our
business, we believe that Anika is well-positioned for continued growth and
profitability improvement in the quarters ahead." The Full Research Report on
Anika Therapeutics Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at: efficiencies
in our business, we believe that Anika is well-positioned for continued growth
and profitability improvement in the quarters ahead

[http://www.AnalystsCorner.com/r/full_research_report/ae5d_ANIK]

--

Sangamo Biosciences Inc. Research Report

On October 23, 2013, Sangamo Biosciences Inc. (Sangamo Biosciences) released
its Q3 2013 results. Sangamo Biosciences registered total revenues of $5.7
million, up 16.3% YoY in Q3 2013. According to the Company, Q3 2013 revenues
were generated from its collaboration agreements with Shire AG and
Sigma-Aldrich Corporation, and research grants. The Company posted a net loss
of $6.1 million in Q3 2013, compared to a net loss of $5.8 million in Q3 2012.
Sangamo Biosciences reported diluted loss per share of $0.11 in Q3 2013, same
as compared to diluted loss per share of $0.11 in Q3 2012. The Full Research
Report on Sangamo Biosciences Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.AnalystsCorner.com/r/full_research_report/52a6_SGMO]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement